Merit Medical (MMSI)
NASDAQ:MMSI
Want to see MMSI full AI Analyst Report?
MMSI Stock Chart & Stats
$68.17
$1.12(1.17%)
At close: 4:00 PM EST
$68.17
$1.12(1.17%)
Day’s Range― - ―
52-Week Range$59.74 - $96.74
Previous CloseN/A
Volume49.13K
Average Volume (3M)869.06K
Market Cap
$3.97B
Enterprise Value$4.09B
Total Cash (Recent Filing)$490.25M
Total Debt (Recent Filing)$821.56M
Price to Earnings (P/E)28.6
Beta0.54
Next Earnings
Jul 29, 2026EPS Estimate
0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.35
Shares Outstanding59,654,854
10 Day Avg. Volume775,419
30 Day Avg. Volume869,061
Financial Highlights & Ratios
PEG Ratio8.40
Price to Book (P/B)3.29
Price to Sales (P/S)3.44
P/FCF Ratio24.53
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue2.65
Enterprise Value/Gross Profit5.45
Enterprise Value/Ebitda11.74
Forecast
1Y Price Target
$87.50Price Target Upside28.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)4.07
Revenue Forecast (FY)$1.62B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow And Operating Cash GenerationSustained high operating cash flow (~$297M TTM) and strong free cash flow (~$274M TTM; OCF > net income ~1.37x) provide durable financial flexibility. This underpins reinvestment, targeted M&A, and debt paydown capacity, cushioning earnings during margin pressure and supporting growth funding.
Improving Margins And ProfitabilityMulti-year margin expansion (gross ~48.7% TTM; net margin ~9% TTM) and recent record first-quarter operating margin reflect better product mix and cost discipline. Higher and more stable margins support durable cash conversion and make earnings less cyclical over the medium term.
Strategic M&A Expanding Higher-growth Therapeutic PortfolioTargeted acquisitions (e.g., View Point) and a formal shift to foundational vs therapeutic reporting accelerate exposure to higher-growth, higher-margin therapy lines. This structural portfolio shift diversifies revenue and creates cross-sell and scale benefits that can sustain faster organic revenue later.
Bears Say
Sizeable Debt Load Despite ImprovementAlthough leverage metrics have improved (debt-to-equity ~0.52), absolute debt (~$846M) is materially higher than prior years. Elevated debt can constrain capital allocation, increase interest vulnerability, and limit the company's ability to absorb prolonged margin compression or fund large opportunistic investments.
Tariff Headwinds Creating Margin UncertaintyOngoing tariff costs (~$15M guidance for 2026) are a persistent gross-margin headwind and create uncertainty around sustained margin expansion. Until tariffs or refund processes are resolved, profitability targets and cash conversion remain exposed to external policy risk.
Divestiture Trimmed Revenue Base And GrowthSelling the DualCap line subtracts a material portion of near-term revenue, creating an inorganic drag and depressing reported organic growth. Replacing that base requires execution from acquisitions or faster therapeutic growth, adding short-to-medium-term pressure on revenue momentum.
Merit Medical Systems News
MMSI FAQ
What was Merit Medical’s price range in the past 12 months?
Merit Medical lowest stock price was $59.74 and its highest was $96.74 in the past 12 months.
What is Merit Medical’s market cap?
Merit Medical’s market cap is $3.97B.
When is Merit Medical’s upcoming earnings report date?
Merit Medical’s upcoming earnings report date is Jul 29, 2026 which is in 43 days.
How were Merit Medical’s earnings last quarter?
Merit Medical released its earnings results on Apr 30, 2026. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.833 by $0.107.
Is Merit Medical overvalued?
According to Wall Street analysts Merit Medical’s price is currently Undervalued.
Does Merit Medical pay dividends?
Merit Medical does not currently pay dividends.
What is Merit Medical’s EPS estimate?
Merit Medical’s EPS estimate is 0.96.
How many shares outstanding does Merit Medical have?
Merit Medical has 59,654,854 shares outstanding.
What happened to Merit Medical’s price movement after its last earnings report?
Merit Medical reported an EPS of $0.94 in its last earnings report, beating expectations of $0.833. Following the earnings report the stock price went down -9.05%.
Which hedge fund is a major shareholder of Merit Medical?
Currently, no hedge funds are holding shares in MMSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merit Medical Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$87.50 (28.36% Upside)
$87.50 (28.36% Upside)
Blogger Sentiment
Bullish
MMSI Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 6.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.99%
12-Months-Change
Fundamentals
Return on Equity
8.95%
Trailing 12-Months
Asset Growth
10.18%
Trailing 12-Months
Company Description
Merit Medical
Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing, and worldwide commercialization of disposable medical products. These devices are crucial for a broad spectrum of diagnostic, therapeutic, and interventional procedures, primarily within the fields of cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two main divisions: Cardiovascular and Endoscopy. Its extensive product portfolio includes advanced solutions for diagnosing and treating conditions in peripheral vessels and organs, as well as a comprehensive suite of cardiac intervention products. The latter encompasses tools for vascular access, angiography, electrophysiology, cardiac rhythm management, fluid and hemodynamic monitoring, hemostasis, and various interventional therapies for heart-related ailments. Additionally, MMSI provides customized procedural solutions, offering critical care items, disinfection protection systems, specialized syringes, manifold kits, and tailored trays and packs. Their offerings further extend to coated tubes and wires, alongside sophisticated sensor components for microelectromechanical systems (MEMS). The company also features pulmonary products, such as laser-cut tracheobronchial stents with their accompanying over-the-wire and direct visualization delivery systems, and dilation balloons used for endoscopic stricture dilation. Gastroenterology products, as well as essential kits and accessories for endoscopy and bronchoscopy procedures, complete their diverse catalog. Merit Medical Systems sells its products to a wide client base, including hospitals and healthcare professionals (physicians, technicians, and nurses) working in alternative care settings. Distribution channels include a direct sales force, authorized distributors, original equipment manufacturer (OEM) partnerships, and custom procedure tray manufacturers, reaching customers throughout the United States and internationally. Founded in 1987, Merit Medical Systems, Inc. has its corporate headquarters situated in South Jordan, Utah.
MMSI Company Deck
MMSI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was largely positive: Merit beat revenue and earnings expectations in Q1, delivered the highest first-quarter operating margin in company history, generated stronger free cash flow, and closed strategic acquisitions (Viewpoint, BioLife, C2) that expand high-growth therapeutic markets. Near-term headwinds include a steep OEM decline in the quarter, tariff impacts and uncertainty, divestiture-related revenue drag, a recent Class I recall (managed as immaterial), and Q2 guidance reflecting some margin and EPS pressure. Management reiterated solid full-year guidance and confidence in organic and inorganic growth and emphasized disciplined cost/control efforts and platform alignment.View all MMSI earnings summariesMMSI Stock 12 Month Forecast
Average Price Target
$87.50
▲(28.36% Upside)
Technical Analysis
ICU Medical
―
Lemaitre Vascular
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
2.69% Insiders
38.24% Mutual Funds
27.51% Other Institutional Investors
6.65% Public Companies and
Individual Investors